510(k) device
Trevo NXT ProVue Retriever
Stryker Neurovascular · Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL, Class II) · First FDA decision Aug 27, 2021, newest Mar 29, 2023Acute ischemic stroke
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
1
Naming "Trevo NXT ProVue"
MAUDE reports
3
Brand "Trevo NXT ProVue", since 2015
PubMed studies
0
Mentioning "Trevo NXT ProVue"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Trevo NXT ProVue Retriever
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K223305 · Decided Mar 29, 2023 · 153 days after receipt
Device type: Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL) · Neurology & Neurosurgery
K210502 · Decided Aug 27, 2021 · 186 days after receipt
Device type: Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Trevo NXT ProVue", any status and sponsor, newest update first.
- Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKePivotal-lookingRecruiting
Raul NogueiraAcademic, hospital or other
NCT05983757 · 584 participants (planned) · Start Apr 2, 2024 · Primary completion Jul 2027
Device: Experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion · For: Ischemic Stroke
Sites: Atlanta, Georgia; Iowa City, Iowa; Toledo, Ohio · 4 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Trevo NXT ProVue", and for the whole product code for context.
This brand
3 reports: 2 malfunction, 1 injury, 0 death
Whole product code POL
97 reports: 40 malfunction, 55 injury, 2 death
Newest reports for this brand
- TREVO NXT PROVUE RETRIEVERMalfunction
MW5171077 · Received Jun 4, 2025 · Event dated May 13, 2025
Device type: Catheter, Thrombus Retriever (NRY)
Device problem as coded: Difficult to Remove
Patient problem as coded: Muscle Weakness/Atrophy; Obstruction/Occlusion; Device Embedded In Tissue or Plaque
MW5159284 · Received Sep 5, 2024 · Event dated Aug 8, 2024
Device type: Catheter, Thrombus Retriever (NRY)
Patient problem as coded: Foreign Body In Patient
- TREVO NXT PROVUE RETRIEVERMalfunction
MW5144948 · Received Aug 24, 2023 · Event dated Aug 3, 2023
Device type: Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL)
Patient problem as coded: Stroke/CVA; Obstruction/Occlusion; Device Embedded In Tissue or Plaque
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1905-2024 · Started Apr 23, 2024 · Posted by FDA May 28, 2024
Reason given: Neurovascular devices did not meet the minimum sample size required for endotoxin testing during manufacturing processes and are out of compliance with the AAMI ST72 standard, so these devices may exceed the acceptable limits of endotoxin levels; high levels of endotoxins may increase the risk of fever, shock and...
Cause as FDA categorized it: Process design · Device type: Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL)
Published research
The most relevant PubMed records for "Trevo NXT ProVue"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code POL.
- Trevo NXT ProVue RetrieverStryker · 510(k) 2020
- Solitaire 2 Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 510(k) 2019
- pRESET Delta Thrombectomy Device and pRESET Delta LITE Thrombectomy DevicePhenox Limited · 510(k) 2025
- pRESET LITE Thrombectomy DevicePhenox Limited · 510(k) 2023
- pRESET Thrombectomy DevicePhenox Limited · 510(k) 2023
- Solitaire X Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 510(k) 2021
- Trevo XP ProVue Retriever and Trevo NXT ProVue RetrieverStryker Neurovascular · 510(k) 2020
- Solitaire Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 510(k) 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.